In a patient receiving apalutamide who requires coronary stent placement, what antiplatelet regimen should be used?

Antiplatelet Regimen for Coronary Stenting in Patients on Apalutamide

In patients receiving apalutamide who require coronary stent placement, use standard dual antiplatelet therapy (DAPT) with aspirin 75-100 mg daily plus clopidogrel 75 mg daily, as there are no known drug interactions between apalutamide and antiplatelet agents that would necessitate regimen modification.

Rationale and Evidence Base

The FDA label for apalutamide does not identify any contraindications or interactions with antiplatelet medications 1. Apalutamide is primarily metabolized by CYP2C8 and CYP3A4, while clopidogrel is a prodrug activated by CYP2C19—these pathways do not overlap in a clinically significant manner 1.

Standard DAPT Protocol

For Acute Coronary Syndrome (ACS) with Stenting:

• Loading: Aspirin 325 mg (if not already on aspirin) plus clopidogrel 600 mg loading dose 2
• Maintenance: Aspirin 75-100 mg daily plus clopidogrel 75 mg daily for at least 12 months 2, 3, 4
• This applies to both bare-metal stents (BMS) and drug-eluting stents (DES) 5, 4

For Elective PCI (Stable Coronary Disease):

• DES: Aspirin 75-100 mg daily plus clopidogrel 75 mg daily for 12 months if bleeding risk is not high 2, 6
• BMS: Aspirin 75-100 mg daily plus clopidogrel 75 mg daily for minimum 1 month, ideally up to 12 months unless high bleeding risk 2, 7

After DAPT Period:

• Continue aspirin 75-100 mg daily indefinitely 5, 8
• If aspirin intolerant: clopidogrel 75 mg daily as monotherapy 5

Critical Considerations Specific to Apalutamide

Bleeding Risk Assessment:

While apalutamide itself does not increase bleeding risk through antiplatelet interactions, assess baseline bleeding risk using:

• HAS-BLED score: If ≥3, consider shorter DAPT duration (3-6 months for elective PCI) 9, 4
• Falls risk is elevated in elderly patients on apalutamide (19% in patients ≥75 years) 1, which increases trauma-related bleeding risk

Monitoring Requirements:

• Proton pump inhibitor (PPI) co-administration is recommended to reduce gastrointestinal bleeding risk 3, 9
• Regular monitoring for skin reactions is essential, as apalutamide causes rash in a significant proportion of patients 10, 11—distinguish drug-induced rash from bleeding manifestations

Alternative P2Y12 Inhibitors

Avoid prasugrel and ticagrelor in favor of clopidogrel for patients on apalutamide:

• Prasugrel and ticagrelor are more potent CYP3A4 substrates and may have unpredictable interactions with apalutamide's CYP3A4 auto-induction 1
• Clopidogrel is the P2Y12 inhibitor of choice when combining with any complex medication regimen 9, 4
• No evidence supports superiority of newer agents over clopidogrel in this specific population

Common Pitfalls to Avoid

1. Do not discontinue DAPT prematurely: Stent thrombosis risk is catastrophic, particularly in the first 30 days post-BMS and first 12 months post-DES 4

2. Do not assume apalutamide requires dose adjustment: Standard apalutamide dosing (240 mg daily) continues unchanged with DAPT 1

3. Do not use triple therapy (aspirin + clopidogrel + anticoagulant) unless there is a compelling indication like atrial fibrillation with high stroke risk—this dramatically increases bleeding risk 9, 12

4. Coordinate with oncology: Ensure prostate cancer treatment is not interrupted unnecessarily, as apalutamide provides significant survival benefit in castration-resistant prostate cancer 13